Silke Kapp‐Schwoerer

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation

Sibylle Cocciardi, Anna Dolnik, Silke Kapp‐Schwoerer et al. · Nature Communications · 2019 · 120 citations · Full text

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with <i>NPM1</i>-mutated AML: results from the AMLSG 09-09 trial

Silke Kapp‐Schwoerer, Daniela Weber, Andrea Corbacioglu et al. · Blood · 2020 · 115 citations · Full text

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group

Frank G. Rücker, Mridul Agrawal, Andrea Corbacioglu et al. · Blood · 2019 · 110 citations · Full text

Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study

Richard F. Schlenk, Peter Paschka, Julia Krzykalla et al. · Journal of Clinical Oncology · 2019 · 104 citations · Full text

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial

Hartmut Döhner, Daniela Weber, Julia Krzykalla et al. · The Lancet Haematology · 2023 · 54 citations

Hematological Malignancy, Oncology, Gemtuzumab Ozogamicin +8